PKI-587 stin At the end of the

At the end of the study

Barreiro EJ

14bS)-10-hydroxy-2

Chemical modification of the M(1) agonist VU0364572 reveals molecular switches in pharmacology and a bitopic binding mode

SCH442416 is selective for A2AR (Ki=0

PKI-587 stin At the end of thePKI 587is an agent targeting the phosphatidylinositol 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in the PI3K mTOR signaling pathway, with potential antineoplastic activity. Upon intravenous administration, PI3K mTOR kinase inhibitor PKI 587 inhibits both PI3K and mTOR kinases, which may result in apoptosis and growth inhibition of cancer cells overexpressing PI3K mTOR. Activation of the PI3K mTOR pathway promotes cell growth, survival,